“The tissue is the issue” was a strong theme of the 2013 CAP/IASLC/AMP guidelines. touchONCOLOGY spoke to Professor Fred Hirsch (The Mount Sinai Hospital, New York City, NY, USA) to discuss his presentation at the European Lung Cancer Summit 2022, providing an update on the current state of personalized medicine and molecular testing in lung cancer.
Question: “The tissue is the issue” was a strong theme of the 2013 CAP/IASLC/AMP guidelines. How have things changed in the last 9 years?
Speaker Disclosure: Fred Hirsch is a member of the advisory board for: Amgen, AstraZeneca/Daiichi,Bristol-Myers, Novartis, NextCure, Novocure, Nectin Therapeutics, Sanofi/Regeneron and OncoCyteSquibb.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the European Lung Cancer Summit 2022
Share this Video
Related Videos In Lung Cancer
Gerard Zalcman, ESMO 2022: IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab in advanced non-small cell lung cancer
First-line immunotherapy is a standard treatment for patients with advanced non-small cell lung cancer. Prof. Gerard Zalcman (Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Institute of Cancer AP-HP Nord, Paris, France) joins touchONCOLOGY to discuss the IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab, aiming to assess if 6-months nivolumab/ipilimumab duration was equivalent to continuation until progression […]
Charles Swanton, ESMO 2022: Mechanism of action and an actionable inflammatory axis for air pollution may induce NSCLC in never-smokers
The mechanistic basis for non-small cell lung cancer (NSCLC) initiation in never smokers is unknown. The air pollutant, particulate matter, is known to be associated with the risk of NSCLC, however a direct cause and mechanism remains difficult to achieve. Prof. Charles Swanton (Francis Crick Institute, London, UK) joins touchONCOLOGY to discuss his study into […]
Catherine A. Shu, ASCO 2022: Updated results from the CHRYSALIS-2 of amivantamab and lazertinib in patients with advanced NSCLC
Dr Catherine Shu (Columbia University Irving Medical Center, New York, NY, USA) discusses the findings of the CHRYSALIS-2 study, which supports the use of amivantamab in certain groups of patients with advanced non-small-cell lung cancer (NSCLC) and represents a chemotherapy-free regimen. The abstract ‘Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!